New CARs on and off the road: challenges and new developments in CAR-T cell therapy

Marc Wehrli; Marcela V Maus

doi:10.1016/j.coph.2021.05.005

New CARs on and off the road: challenges and new developments in CAR-T cell therapy

Curr Opin Pharmacol. 2021 Aug:59:116-126. doi: 10.1016/j.coph.2021.05.005. Epub 2021 Jun 28.

Authors

Marc Wehrli¹, Marcela V Maus²

Affiliations

¹ Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
² Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. Electronic address: mvmaus@mgh.harvard.edu.

PMID: 34198161
DOI: 10.1016/j.coph.2021.05.005

Abstract

Building on the tremendous success of chimeric antigen receptor T-cell therapy in hematological malignancies, there are efforts under way to overcome the challenges associated with this treatment and expand its application to solid tumors. In this fast-evolving field, new therapeutic options are constantly generated, tested in model systems, and further evaluated in clinical trials. In this review, we provide an overview of recent challenges and developments associated with engineered T cells and chimeric antigen receptor T-cell applications. We report on the most recent progress in hematological malignancies and highlight technical advances for applications in solid tumors.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Cell- and Tissue-Based Therapy
Humans
Immunotherapy, Adoptive
Neoplasms* / therapy
Receptors, Antigen, T-Cell / genetics
Receptors, Chimeric Antigen*
T-Lymphocytes

Substances

Receptors, Antigen, T-Cell
Receptors, Chimeric Antigen